Company Overview

Company name: Tilray (NAS: TLRY)
Also known as: Lafitte Ventures
Description: Manufacturer of medical cannabis and cannabinoid products. The company operates as an exporter of medical cannabis products from North America to the European Union and is committed to the understanding of medical cannabis and collaborates with renowned hospitals and universities around the world to study the safety and efficacy of cannabis in treating a wide range of diseases and conditions.
Year founded: 2013
Parent company:
Industry: Healthcare | Group: Pharmaceuticals and Biotechnology | Code:
Website: www.tilray.com
Employees: 313
City: Nanaimo
State: British Columbia
Country: Canada
Region: Americas

Financial Highlights

Start up capital raised (USD Million): 200.82
Business status: Generating Revenue
Ownership: Publicly Held
Exchange: NAS
Ticker: TLRY
Revenue (USD Million): 32.71
Gross profit (USD Million): 14.09
Net income (USD Million) -39.62
Enterprise value: 13,406.76
Earnings before interest, tax, depreciation and amortization (EBITDA): -34.88
Fiscal period: TTM 3Q2018
Financing Status: The company raised $153 million in its initial public offering on the Nasdaq stock exchange under the ticker symbol of TLRY on July 19, 2018. A total of 9,000,000 shares were sold at a price of $17 per share. After the offering, there was a total of 91,794,042 outstanding shares (excluding the over-allotment option) priced at $17 per share, valuing the company at $1.56 billion. The underwriters were granted an option to purchase up to an additional 1,350,000 shares from the company to cover over-allotments, if any.
Number of active investors:
Profile last updated: 09-Nov-2018
Last known valuation: 1,560.50
Last known valuation date: 19-Jul-2018